“We’re Checking” Is Not a Regulatory Position
Answer with Confidence. A hedge is the most expensive answer a regulated organization can give Somewhere between a confirmed safety
eCTD 4.0 Is No Longer a Future Problem for Global Sponsors
The eCTD 4.0 implementation timeline is now materially different across Japan, the EU and the US, forcing global sponsors to
AI Readiness in Pharma Depends on Data Governance: Munnik’s 2026 Midyear Reality Check
Why data governance for AI in pharma will determine which pharmaceutical organizations turn AI pilots into reliable regulatory operations Large
Electronic Product Information (ePI) and ISO IDMP: Why Structured Content Authoring Is the Prerequisite, Not the Nice-to-Have
The operating model shift from flat documents to governed, reusable product information. For decades, product information has lived as a
6 ePI Implementation Challenges Pharma Companies Must Solve
Why ePI Implementation Challenges Are Increasing ePI is inevitable. Most pharma organizations have accepted that ePI is not optional. According
CCDS vs Local Labels: Managing Global Labeling Deviations
How pharmaceutical teams manage CCDS vs local labels while maintaining compliance, traceability, and governance A Real World Scenario A multinational
ePI and FHIR: A Practitioner’s Walkthrough of the FHIR ePI Implementation Guide
What Pharma Companies Need to Know About ePI FHIR When the European medicines regulatory network adopted the EU ePI Common
ePI vs SPL: Preparing for EU Electronic Product Information and FDA Structured Product Labeling
How EU ePI and FDA SPL Create Parallel Labeling Workflows A director of Regulatory Affairs at a mid-sized pharma company
AI Won’t Fix Bad Data: Why Data Quality Is the Real Gatekeeper for AI in Pharma
The conversation about data quality for AI in pharma has shifted. It is no longer an upstream IT concern or
AI in Regulatory Affairs: Cutting Through the Hype
How governed, structured content enables responsible AI in life sciences. Artificial intelligence (AI) has moved from a buzzword to a
Digital Twins in Regulatory Affairs: Hype or the Next Submission Era?
Digital Twin Pharma: The Future of Regulatory Submissions? Digital twins have transformed industries such as aerospace, automotive, and manufacturing by
Enhancing The Patient Experience with ePI
ePI is reshaping pharma’s digital future. Learn how structured content and AI help life sciences companies meet compliance faster, with accuracy, agility, and scale.
A Primer on the Structured Content Landscape: Why the Future of Pharma Depends on Structured Content in Life Sciences
Explore how structured content transforms life-sciences: driving reuse, traceability, regulatory readiness, and faster time-to-market in pharma. Includes download.
AI-SCA and the Digital Regulatory Roadmap: Accelerating eCTD 4.0 Readiness in Pharma
Explore how AI-SCA supports pharma’s shift to digital-first regulation (ePI, IDMP, CTD 4.0) by enabling modular, metadata-rich content, faster review, and audit-ready operations.
3 Ways Structured Content Accelerates ePI Readiness
Explore how structured content authoring accelerates ePI readiness in pharma—driving flexibility, multilingual reuse and machine-readable compliance.
7 Use Cases for AI in Structured Authoring for Regulatory Teams
Discover how AI-powered structured content authoring transforms pharma documentation — from labeling and safety narratives to CTD module alignment and metadata tagging.
DIA Europe Takeaways: AI, Componentization, and Standards
Recently, Docuvera attended DIA Europe 2023, a conference organized by the Drug Information Association (DIA), a global nonprofit. The event aims to bring together Life Sciences professionals to exchange knowledge and collaborate to improve healthcare worldwide and provides a platform to discuss the latest developments in healthcare and regulatory science.